Clinical Study Confirms Molecular Breast Imagings High Cancer Detection Rate in Dense

first_img News | Mammography | August 14, 2019 Imago Systems Announces Collaboration With Mayo Clinic for Breast Imaging Image visualization company Imago Systems announced it has signed a know-how license with Mayo Clinic. The multi-year… read more For more information, visit www.gammamedica.com References:1. Shermis, RB, Wilson, K, et al. Supplemental Breast Cancer Screening With Molecular Breast Imaging for Women With Dense Breast Tissue. American Journal of Roentgenology. August 2016.2. Pisano ED, Gatsonis C, Hendrick E, et al. Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med. October 2005.3. Boyd NF, Guo H, Martin LJ, et al. Mammographic Density and the Risk and Detection of Breast Cancer. N Engl J Med. January 2007.4. Rhodes DJ, Hruska CB, Conners AL, et al. JOURNAL CLUB: Molecular Breast Imaging at Reduced Radiation Dose for Supplemental Screening in Mammographically Dense Breasts. American Journal of Roentgenology. 2015;204(2):241-251.5. Hruska CB, Conners AL, Jones KN, et al. Diagnostic Workup and Costs of a Single Supplemental Molecular Breast Imaging Screen of Mammographically Dense Breasts. American Journal of Roentgenology. 2015;204(6):1345-1353. doi:10.2214/AJR.14.13306.6. Rhodes DJ, Hruska CB, Conners AL, et al. JOURNAL CLUB: Molecular Breast Imaging at Reduced Radiation Dose for Supplemental Screening in Mammographically Dense Breasts. American Journal of Roentgenology. 2015;204(2):241-251.7. Rhodes DJ, Hruska CB, Conners AL, et al. JOURNAL CLUB: Molecular Breast Imaging at Reduced Radiation Dose for Supplemental Screening in Mammographically Dense Breasts. American Journal of Roentgenology. 2015;204(2):241-251. FacebookTwitterLinkedInPrint分享 Related Content Read the article, “The Benefits of Molecular Breast Imaging.” News | Brachytherapy Systems | August 14, 2019 Efficacy of Isoray’s Cesium Blu Showcased in Recent Studies August 14, 2019 — Isoray announced a trio of studies recently reported at scientific meetings and published in medica read more News | Radiation Therapy | August 15, 2019 First Patient Enrolled in World’s Largest Brain Cancer Clinical Trial Henry Ford Cancer Institute is first-in-the-world to enroll a glioblastoma patient in the GBM AGILE Trial (Adaptive… read more News | Neuro Imaging | August 16, 2019 ADHD Medication May Affect Brain Development in Children A drug used to treat attention-deficit/hyperactivity disorder (ADHD) appears to affect development of the brain’s… read more Images of regions of interest (colored lines) in the white matter skeleton representation. Data from left and right anterior thalamic radiation (ATR) were averaged. Image courtesy of C. Bouziane et al. Read the article, “Molecular Breast Imaging Deemed Cost-Effective Secondary Breast Cancer Screening Technology.” August 2, 2016 — A retrospective study in American Journal of Roentgenology (AJR) August issue confirmed Gamma Medica’s molecular breast imaging (MBI) technology’s high incremental cancer detection rate of 7.7 cancers per thousand and overall clinical effectiveness as a secondary screening tool in finding 13 malignancies among 1,696 women with dense breast tissue following mammograms that read negative for cancer.[1] Approximately 85 percent of these cancers were confirmed to be node negative (with 7.6 percent being confirmed node positive, and 7.6 percent being unknown), indicating they were detected at an early stage and therefore presented a better prognosis.“This study offers practice-based, clinical proof that for women with dense breast tissue – roughly half the female population in the United States alone – MBI is a powerful tool that finds cancer where a mammogram alone can miss it,” said Robin Shermis, M.D., one of the study’s authors and the medical director at the ProMedica Breast Care Center, Toledo, Ohio, where the research took place. The community-based study used data from routine clinical practice at the facility from 2011 to 2014, focusing on women with aged 25-90 with heterogeneously and extremely dense breast tissue. “Following up a mammogram with MBI enables detection of an additional 7.7 cancers per 1000 women screened. It’s also safe and easy to use, delivers almost instantaneous results and is fits perfectly within our workflow,” Shermis said.For women with dense breast tissue, sensitivity of standardized anatomical screening technology drops significantly (from 85 to 65 percent), making it insufficient to reliably detect cancerous tumors.[2] Meanwhile, these women are up to two times more likely to develop breast cancer. Shermis’s patient at ProMedica, Dianne Anderson, read negative for cancer during her mammogram, but because she had dense breast tissue, Shermis recommended she try MBI3. The MBI showed she had breast cancer, which she has successfully overcome thanks to early detection and multiple treatments.“Without MBI, I would have no idea I had breast cancer, because my mammogram said I was cancer-free,” Anderson said. “Had I not undergone that MBI after my mammogram, I truly believe I would’ve been in a much more serious stage of cancer. I’m just so thankful MBI was there.”The study also confirmed that in addition to delivering a high cancer detection rate, nuclear breast imaging affords patients with a high positive predictive value, a high invasive cancer detection rate, minimal radiation and rapid interpretation allowing for real-time readings. Determined to spread awareness on the high degree of certainty MBI offers compared to more conventional screening technologies, the manufacturer of the LumaGEM MBI system used in the study, Gamma Medica, launched the educational Be Certain campaign last month through creating a dedicated website and various social media channels.“This new study in the AJR provides further evidence that women with dense breast tissue have more comfortable and less stressful alternatives to standardized secondary screening studies. These recent clinical results suggest there is a real alternative to the risk of misdiagnosis and unnecessary biopsies. Our recently launched Be Certain campaign offers more clinical information to a large population of underserved patients,” said Phil Croxford, Gamma Medica’s CEO, pointing to the need to confront the 40,000 deaths at the hands of breast cancer each year.The AJR study serves as a follow-up to the Mayo Clinic’s prospective, blinded study that was published in the AJR last year that showed MBI yields superior imaging to a mammogram and low-radiation exposure comparable to that of a mammogram, and that MBI also:•    Increases breast cancer detection rates by 400 percent.4•    Decreases the cost per cancer detected by 15 percent compared to mammogram alone.5•    Reduces biopsies by 50 percent compared to other modalities.6•    Is far more comfortable than a mammogram and other adjunct breast screening technologies.“This new AJR study shows that what we learned from the Mayo Clinic and AJR studies last year really holds true in a large, routine, community based clinical practice in the real world,” Shermis said. “MBI delivers on its promise and is critical to serving the need of a vast patient population to be certain about their breast health.” News | Pediatric Imaging | August 14, 2019 Ultrasound Guidance Improves First-attempt Success in IV Access in Children August 14, 2019 – Children’s veins read more News | Cardiovascular Ultrasound | August 07, 2019 Contrast Use in First Transthoracic Echocardiogram for Heart Failure Reduces Repeat Testing Heart failure is the fourth most common cause for all admission to U.S. hospitals, and it is the most common reason for… read more News | Breast Imaging | August 02, 2016 Clinical Study Confirms Molecular Breast Imaging’s High Cancer Detection Rate in Dense Breast Tissue American Journal of Roentgenology study used the LumaGEM MBI system on 1,696 women to detect 13 cancers missed by routine mammograms, reporting MBI yielded a high detection rate and low biopsy rate News | PET-CT | August 15, 2019 United Imaging Announces First U.S. Clinical Installation of uExplorer Total-body PET/CT United Imaging announced that its uExplorer total-body positron emission tomography/computed tomography (PET/CT) system… read more News | CT Angiography (CTA) | August 06, 2019 Artificial Intelligence Improves Heart Attack Risk Assessment When used with a common heart scan, machine learning, a type of artificial intelligence (AI), does better than… read more Image courtesy of Imago Systems News | Colonoscopy Systems | August 06, 2019 Rise in Early Onset Colorectal Cancer Not Aligned With Screening Trends A new study finds that trends in colonoscopy rates did not fully align with the increase in colorectal cancer (CRC) in… read more News | Artificial Intelligence | August 13, 2019 Artificial Intelligence Could Yield More Accurate Breast Cancer Diagnoses University of California Los Angeles (UCLA) researchers have developed an artificial intelligence (AI) system that… read more last_img

Leave a Reply

Your email address will not be published. Required fields are marked *